CSBR 250117 7.50C (CSBR250117C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CSBR250117C7500

Watchlist

1.82
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaJan 17 07:05 ET
A Look At The Intrinsic Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Yahoo FinanceJan 12 08:22 ET
Champions Oncology Integrates Cytek Aurora Flow Cytometers
TipRanksJan 8 08:30 ET
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio With New Technology and Additional Leadership
AccesswireJan 8 08:00 ET
Momentum Reigned 2024: Buy-rated U.S. Stocks With the Highest RSI
Seeking AlphaJan 3 13:28 ET
Private Equity Firms Invested in Champions Oncology, Inc. (NASDAQ:CSBR) up 19% Last Week, Insiders Too Were Rewarded
Yahoo FinanceDec 22, 2024 09:04 ET

Comments

Stock_Drift

Dec 12, 2024 04:24

Pre Market Ticks. 5:23am 12/12

$Alset (AEI.US)$ $SRM Entertainment (SRM.US)$ $Champions Oncology (CSBR.US)$ $Safe & Green (SGBX.US)$ $JIADE (JDZG.US)$ $Charles & Colvard (CTHR.US)$ $Coeptis Therapeutics (COEP.US)$ $Nuburu (BURU.US)$ $DBV Technologies (DBVT.US)$ $Wheeler Real Estate Investment Trust Inc (WHLR.US)$ $AmpliTech Group (AMPG.US)$ $Palisade Bio (PALI.US)$
📊⚡️📊

Jaguar8

Dec 11, 2024 15:01

NEWS ER

$Champions Oncology (CSBR.US)$
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
Wednesday, 11th December at 4:00 pm
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.
Second Quarter and Recent Highlights:...

jimmy the trader

Sep 11, 2024 16:09

Very nice 👍 late entry but still made good

$Champions Oncology (CSBR.US)$

Jaguar8

Sep 11, 2024 15:54

NEWS ER

$Champions Oncology (CSBR.US)$
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
Positive
▪️Revenue increased 12% year-over-year to $14.1 million
▪️Margin improved to 50% from 38.8% in the previous year
▪️Achieved adjusted EBITDA of $2.0 million, compared to a loss of $1.7 million last year
▪️Reported net income of $1.3 million
▪️Total costs and operating expenses decreased by $2.4 million or 15.8%
▪️Cost of oncology services decreased by 8.0%
▪️...

Trytosaveabit

Sep 11, 2024 15:15

$Champions Oncology (CSBR.US)$ First Quarter Highlights:
Total revenue increased 12% to $14.1 million
Margin improved to 50%
Adjusted EBITDA of $2.0 million
Net income of $1.3 million
EPS 0.01 a 94%+ increase